Panagora Asset Management’s Fulcrum Therapeutics FULC Stock Holding History

Panagora Asset Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$350K	Sell	95,521 -148,044	-61%	-$901K	﹤0.01%	991
2026 Q1	$1.87M	Buy	+243,565	New	+$2.26M	0.01%	599
2024 Q4	–	Sell	-97,891	Closed	-$349K	–	1181
2024 Q3	$349K	Buy	+97,891	New	+$726K	﹤0.01%	1009
2023 Q2	–	Sell	-22,299	Closed	-$63.6K	–	1335
2023 Q1	$63.6K	Sell	22,299 -937	-4%	-$8.39K	﹤0.01%	1424
2022 Q4	$169K	Sell	23,236 -5,825	-20%	-$38K	﹤0.01%	1386
2022 Q3	$235K	Buy	29,061 +415	+1%	+$2.97K	﹤0.01%	1338
2022 Q2	$140K	Hold	28,646	–	–	﹤0.01%	1426
2022 Q1	$677K	Buy	28,646 +106	+0.4%	+$1.5K	﹤0.01%	1104
2021 Q4	$505K	Buy	28,540 +133	+0.5%	+$2.63K	﹤0.01%	1211
2021 Q3	$801K	Buy	28,407 +27,579	+3,331%	+$523K	﹤0.01%	1069
2021 Q2	$9K	Buy	828 +436	+111%	+$4.41K	﹤0.01%	2295
2021 Q1	$5K	Hold	392	–	–	﹤0.01%	2575
2020 Q4	$5K	Buy	+392	New	+$4.43K	﹤0.01%	2458

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Panagora Asset Management's FULC Position: Q2 2026 in Review

Panagora Asset Management reduced its Fulcrum Therapeutics (FULC) stake by 61% in Q2 2026, selling an estimated $901K and leaving 95,521 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #991.

Panagora Asset Management first reported a position in FULC in Q4 2020 and has held it in 13 quarters since. The position peaked at $1.87M in Q1 2026. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Panagora Asset Management held 95,521 shares of Fulcrum Therapeutics worth $350K as of Q2 2026.
Panagora Asset Management sold 148,044 Fulcrum Therapeutics shares in Q2 2026, an estimated $901K.
Fulcrum Therapeutics made up ﹤0.01% of Panagora Asset Management's portfolio in Q2 2026, its #991 holding.
Panagora Asset Management first reported a position in Fulcrum Therapeutics in Q4 2020 and has held it in 13 quarters since.
Panagora Asset Management's Fulcrum Therapeutics position peaked at $1.87M in Q1 2026.
154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.